Telix Pharmaceuticals (TLX) said late Wednesday the first patients with metastatic hormone-sensitive prostate cancer have been dosed with TLX597-Tx in a phase 2 trial at St Vincent's Hospital in Sydney, Australia.

The OPTIMAL-e trial will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA2 study which recently completed patient enrollment, the firm said.